ITMCTR1900002294
Not yet recruiting
未知
Research for the Clinical Effect and Immune Mechanism of Soothing the Lung and Anti-fever, Resolving Blood-stasis and Unblocking Collaterals in the Treatment of Mycoplasma Pneumoniae Pneumonia in Children
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Mycoplasma pneumoniae pneumonia in children meets the western medical diagnostic criteria;
- •2\. Thermal process\>48h and\<96h;
- •3\. The cough is prominent and persistent,and graded\=2;
- •4\. Peripheral white blood cell (WBC)count was normal;
- •5\. It conforms to the TCM syndrome standard of wind\-heat closed the lung or poison\-heat closed the lung;
- •6\. The children are aged 5\~14;
- •7\. The informed consent process is in compliance with regulations,the legal representative of the children signed the informed consent files.
Exclusion Criteria
- •1\. For children with severe pneumonia, segmental or lobar parenchymal infiltration shadow similar to that of bacterial pneumonia can be clearly diagnosed as bacterial pneumonia or viral pneumonia, and simple hilar lymphadenoma with large through the chest X\-ray manifestations;
- •2\. Those who have used macrolide antibiotics and hormones before enrollment;
- •3\. Confirmed mycoplasma pneumoniae infection in the past 3 months;
- •4\. Pulmonary complications, including pleural effusion or empyema, pneumothorax, pulmonary abscess, bronchopleural fistula, necrotizing pneumonia, and acute respiratory failure, have occurred;
- •5\. Pulmonary infection caused by primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory tract malformation, abnormal lung development, aspiration pneumonia, lung malignancy and other basic diseases;
- •6\. Patients with severe malnutrition, rickets and severe primary diseases of heart, brain, liver, kidney and hematopoietic system;
- •7\. Allergic constitution (allergic to more than 2 kinds of substances), or allergic to macrolide antibiotics and components of jinzhen oral liquid;
- •8\. According to the researcher's judgment, those who are not suitable for enrollment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical study on the clinical efficacy and immune function of anticancer prescription combined with chemotherapy in patients with bladder cancerITMCTR1900002444Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Completed
Not Applicable
Clinical and immunological analysis on the effect of LEM in the adoptive immunotherapy using autologous activated lymphocytes in patients with incurable cancerIncurable cancerJPRN-UMIN000012283Kawasaki Medical School20
Active, not recruiting
Phase 1
A study to investigate the clinical and immunological effects on field cancerization in patients treated with PD-1 inhibition for advanced or metastatic cutaneous squamous cell carcinomaadvanced or metastatic cutaneous squamous cell carcinomaMedDRA version: 24.1Level: LLTClassification code 10085908Term: Cutaneous squamous cell carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-006372-17-DEMuehlenkreiskliniken AoeR20
Completed
Not Applicable
A study of biological, immunological and physiological parameters describing skin irritation induced by a physical stimulus in healthy male volunteersskin irritation10014982NL-OMON38828TNO30
Active, not recruiting
Phase 1
A study of safety, effect on the immune system and blood clotting of BAX855 (factor VIII of blood clotting) in pediatric patients who have not received or received minimal treatment for their severe hemophilia A.EUCTR2015-002136-40-ITBAXALTA INNOVATIONS GMBH120